Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Access the interviews in their entirety at:
TBH:https://www.redchip.com/assets/access/tbh_accessFBLG: https://www.redchip.com/assets/access/fblg_access
In an exclusive interview, Lavell Juan Malloy II, CEO and Co-Founder of Brag House, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how Brag House is redefining brand engagement for Gen Z through its social gaming and data-driven platform. Malloy highlights the Company's unique ability to connect brands with the highly sought-after Gen Z demographic by fusing college sports rivalries, casual gaming, and community-based interaction into a seamless digital experience. With proven success through partnerships with Coca-Cola, McDonald's, the Denver Broncos, and Learfield, Brag House delivers industry-leading engagement metrics-including CPC and CPM rates significantly below industry averages. Malloy also outlines the Company's strategic alliance with Learfield, powering Brag's national expansion across over 200+ universities, and shares insights into Brag's multi-tiered monetization model and scalable B2B data solutions-positioning the Company at the convergence of three massive markets: gaming, advertising, and analytics.
Pete O'Heeron, CEO of FibroBiologics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to spotlight the company's pioneering work in fibroblast-based cell therapies. O'Heeron discusses the advantages of fibroblasts over traditional stem cells, highlighting their regenerative and immunomodulatory properties, scalability, and safety profile. He outlines the Company's robust pipeline, led by CYWC628 for diabetic foot ulcers, which is slated to enter a Phase 1/2 clinical trial in Australia later this year. Additional programs, including CybroCell™ for degenerative disc disease and CYMS101 for multiple sclerosis, target multi-billion-dollar markets and are supported by promising preclinical and early human data. With over 240 issued and pending patents, a recently completed cGMP-compliant cell bank, and a seasoned leadership team, FibroBiologics is advancing a scalable, off-the-shelf platform poised to transform treatment for chronic diseases and deliver significant long-term value to shareholders.
TBH and FBLG are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About Brag House
Brag House is a leading media technology gaming platform dedicated to transforming casual college gaming into a vibrant, community-driven experience. By seamlessly merging gaming, social interaction, and cutting-edge technology, the Company provides an inclusive and engaging environment for casual gamers while enabling brands to authentically connect with the influential Gen Z demographic. For more information, visit www.braghouse.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:Dave GentryRedChip Companies Inc.1-407-644-4256info@redchip.com
SOURCE: RedChip Companies, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Allient Inc. (NASDAQ:ALNT) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Allient's (NASDAQ:ALNT) stock is up by a considerable 82% over the past three months. However, we wonder if the company's inconsistent financials would have any adverse impact on the current share price momentum. Particularly, we will be paying attention to Allient's ROE today. Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Put another way, it reveals the company's success at turning shareholder investments into profits. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Allient is: 3.6% = US$9.8m ÷ US$273m (Based on the trailing twelve months to March 2025). The 'return' is the income the business earned over the last year. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.04 in profit. See our latest analysis for Allient We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. It is hard to argue that Allient's ROE is much good in and of itself. Even compared to the average industry ROE of 11%, the company's ROE is quite dismal. As a result, Allient's flat earnings over the past five years doesn't come as a surprise given its lower ROE. We then compared Allient's net income growth with the industry and found that the average industry growth rate was 13% in the same 5-year period. Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Allient's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. Allient's low three-year median payout ratio of 9.9%, (meaning the company retains90% of profits) should mean that the company is retaining most of its earnings and consequently, should see higher growth than it has reported. Moreover, Allient has been paying dividends for at least ten years or more suggesting that management must have perceived that the shareholders prefer dividends over earnings growth. In total, we're a bit ambivalent about Allient's performance. Even though it appears to be retaining most of its profits, given the low ROE, investors may not be benefitting from all that reinvestment after all. The low earnings growth suggests our theory correct. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Fox News
14 minutes ago
- Fox News
Washington pastor on prayer and grieving after tragic loss of life in Texas floods
All times eastern Maria Bartiromo's Wall Street Maria Bartiromo's Wall Street FOX News Radio Live Channel Coverage
Yahoo
18 minutes ago
- Yahoo
Jim Cramer Reiterates $200 PT for Palantir
Palantir Technologies Inc. (NASDAQ:) is one of the stocks that Jim Cramer shed light on. During the episode, Cramer reiterated his $200 price target for the company stock, as he said: 'If the market could mount such a comeback after a very difficult moment, which was Liberation Day, and against all these institutions, then why not keep buying? It's working. Okay, so now you can quibble over what these people are buying. There's a lot of money going into the high-flying stocks, stocks like Palantir, and I told you, $50 goes to $100, $100 goes to $200.' A software engineer manipulating a vast network of code on virtual monitors. Palantir (NASDAQ:PLTR) creates software platforms that uncover patterns in complex data, support operational decisions. The company integrates AI tools to improve intelligence analysis and organizational workflows. Cramer mentioned the stock during the July 1 episode and said: 'The biggest winner of the first half was, of course, Palantir Technologies, the government enterprise software company with the stock that's beloved by individual investors. It finished the first six months of the year up more than 80%. The skeptics will point to Palantir's nosebleed valuation, I mean, this is now a $308 billion company, trades at a mere 225 times this year's earnings estimates, or the fact that very few people can articulate what their software really does. But that's par for the course with enterprise software stories, and Palantir's got tremendous growth with surprisingly high margins. Just as important, the people who run the company are simpatico with the Trump administration, especially the Defense Department. Good way to win business. They want to change the Defense Department in a way that I think you and I might want, but they'll just say it in a potty-mouth way. Palantir's now a $130 stock, and I've said for a while now that it's headed to $200, not because of the fundamentals, but because that's how momentum stocks behave. Just remember, if you've got huge gains in this one, those gains don't count until you're reading the register on part of the position. Take something off the table, let the rest run, play with the house's money.' While we acknowledge the potential of PLTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
